Market capitalization | $14.21m |
Enterprise Value | $13.16m |
P/E (TTM) P/E ratio | negative |
P/B ratio (TTM) P/B ratio | negative |
Cash position | $2.25m |
Short interest | 0.23% |
As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.
1 Analyst has issued a forecast Akari Therapeutics Plc Sponsored ADR:
1 Analyst has issued a forecast Akari Therapeutics Plc Sponsored ADR:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -1.85 -1.85 |
-
|
EBIT (Operating Income) EBIT | -1.85 -1.85 |
-
|
Net Profit | -2.90 -2.90 |
-
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.
Head office | United Kingdom |
CEO | Samir Patel |
Founded | 2004 |
Website | www.akaritx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.